

Citations of CCRA Publications

(Last updated: 2017-04-28)

CCRA investment reports

Journal Articles

- 1) Almatar, A. et al. (2014). Practice patterns and perceptions of survivorship care in Canadian genitourinary oncology: A multidisciplinary perspective. *Canadian Urological Association Journal*, 8(11–12):409–17.
- 2) Barr, R.D. (2011). Adolescents, young adults, and cancer—the international challenge. *Cancer*, 117(S10):2245–9.
- 3) Bender, J.L. et al. (2012). Fostering partnerships in survivorship care: report of the 2011 Canadian genitourinary cancer survivorship conference. *Journal of Cancer Survivorship*, 6(3):296–304.
- 4) Bender, J.L. et al. (2013). A lot of action, but not in the right direction: Systematic review and content analysis of smartphone applications for the prevention, detection, and management of cancer. *Journal of Medical Internet Research*, 15(12):e287.
- 5) Boormans, J.L. & Zwarthoff, E.C. (2016). Limited funds for bladder cancer research and what can we do about it. *Bladder Cancer*, 2(1):49–51.
- 6) Branton, P.E. (2008). Does Canadian research investment relate to cancer burden? *The Lancet Oncology*, 9(2):82–3.
- 7) Campbell, D. et al. (2010). Bibliometrics as a performance measurement tool for research evaluation: The case of research funded by the National Cancer Institute of Canada. *American Journal of Evaluation*, 31(1):66–83.
- 8) Carter, A. Jr. & Nguyen, C.N. (2012). A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. *BMC Public Health*, 12(526).
<http://www.biomedcentral.com/1471-2458/12/526>
- 9) Carter, A. Jr., Delarosa, B. & Hur, Hannah. (2015). An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States value. *Health Research Policy and Systems*, 13(62). <http://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-015-0050-7>
- 10) Carter, H.E., Schofield, D.J. & Shrestha, R. (2016). The productivity costs of premature mortality due to cancer in Australia: Evidence from a microsimulation model. *PloS ONE*, 11(12):e0167521.
- 11) Castillo-Pelayo, T. et al. (2015). The importance of biobanking in cancer research. *Biopreservation and Biobanking*, 13(3):172–7.
- 12) de Oliveira, C. et al. (2013). Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: A population-based descriptive study. *CMAJ Open*, 1(1):E1–E8.
- 13) Eckhouse, S. et al. (2008). Trends in the global funding and activity of cancer research. *Molecular Oncology*, 2(1):20–32.
- 14) Fassbender, K. & Watanabe, S.M. (2015). Early palliative care and its translation into oncology practice in Canada: barriers and challenges. *Annals of Palliative Medicine*, 4(3):135–49.
- 15) Hanly, P., Pearce, A. & Sharp, L. (2014). The cost of premature cancer-related mortality: a review and assessment of the evidence.

Expert Review of Pharmacoeconomics & Outcomes Research, 14(3):355–77.

- 16) Howell, D. (2011). Palliative care research: urgent need for investment. *International Journal of Palliative Nursing*, 17(10):471.
- 17) Kanavos, P. et al. (2010). The role of funding and policies on innovation in cancer drug development. *eCancer Medical Science*, 4. DOI: 10.3332/ecancer.2010.164
- 18) Katz, L. et al. (2014). Using health care utilization and publication patterns to characterize the research portfolio and to plan future research investments. *PLoS ONE*, 9(12):e114873.
- 19) Leatherdale, S.T. (2015). An examination of the co-occurrence of modifiable risk factors associated with chronic disease among youth in the COMPASS study. *Cancer Causes & Control*, 26(4):519–528.
- 20) Lynch, M.E. et al. (2009). Research funding for pain in Canada. *Pain Research and Management*, 14(2):113–5.
- 21) Matei, M.C. et al. (2015). Cancer research investment: “Top-Down” versus bibliometric approach. *Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi*, 119(3):828–34.
- 22) Matei, M.C., Chirica, V. & Azoicai, D. (2015). A review of cancer research funding. *Social Research Reports*, 27:3–25.
- 23) Mauri, D. et al. (2013). Cancer pain: Global awareness and guideline recommendation. *Forum of Clinical Oncology*, 4(3):20–31.
- 24) Meredith, A.J. et al. (2015). A model to estimate frozen tissue collection targets in biobanks to support cancer research. *Biopreservation and Biobanking*, 13(5):356–62.
- 25) Moretto, P. et al. (2014). Kidney cancer survivorship survey of urologists and survivors: The gap in perceptions of care, but agreement on needs. *Canadian Urological Association Journal*, 8(5–6):190–4.
- 26) Patafio, F.M. et al. (2015). Cancer mortality and published research output: Is there any relationship? 2015 ASCO Annual Meeting, *Journal of Clinical Oncology*, 33(suppl), Abstract 6596.
- 27) Patafio, F.M. et al. (2016). Research output and the public health burden of cancer: is there any relationship? *Current Oncology*, 23(2):75–80.
- 28) Riley, B.L. (2013). “The Magic Is in the Mix”: Lessons From Research Capacity Building in the Canadian Tobacco Control Community, 2000–2010. *Canadian Journal of Public Health*, 104(2):e173–6.
- 29) Sanson-Fisher, R. et al. (2010). Quality of life research: is there a difference in output between the major cancer types? *European Journal of Cancer Care*, 19(6):714–20.
- 30) Sleeman, J. & Steeg, P.S. (2010). Cancer metastasis as a therapeutic target. *European Journal of Cancer*, 46(7):1177–80.

Book Chapters

- 1) Clarke, J.N. (2016). *Health, Illness, and Medicine in Canada*. (7th Ed.). Toronto: Oxford University Press. [use of figure]
- 2) Hurlbert, M. et al. (2014). Landscape analysis of MBC research. In the Metastatic Breast Cancer (MBC) Alliance, *Changing the Landscape for People Living with Metastatic Breast Cancer. Metastatic Breast Cancer Landscape Analysis: Research Report*. http://www.mbcalliance.org/docs/MBCA_Full_Report_Landscape_Analysis.pdf
- 3) Kerner, J. (2010). Integrating science with service in cancer control: closing the gap between discovery and delivery. In J.M. Elwood & S.B. Sutcliffe (Eds.), *Cancer Control*. Oxford: Oxford University Press.
- 4) Picco, Gail. (2017). *Cap in Hand: How Charities are Failing the People of Canada and the World*. Toronto: Civil Sector Press.
- 5) Stamatakis, K.A., Vinson, C.A. & Kerner, J.F. (2012). Dissemination and implementation research in community and public health settings. In R.C. Brownson, G.A. Colditz & E.K. Proctor (Eds.), *Dissemination and Implementation Research in Health: Translating Science to Practice*. New York: Oxford University Press. (pp. 359-80)
- 6) Gosain, R., Gill, A.S. & Miller, K.D. (2015). Cancer Care in Canada. In K.D. Miller & M. Simon (Eds.), *Global Perspectives on Cancer: Incidence, Care, and Experience*. Santa Barbara, CA: Praeger.

Newspaper Articles

- 1) André Picard, "How cancer research dollars are spent." *The Globe and Mail*, September 12, 2007, p. A1.
- 2) André Picard, "Five cents of every research dollar goes to cancer research – is it enough?" *The Globe and Mail*, August 26, 2008, p. L4.
- 3) André Picard, "About 3% of cancer research focuses on childhood illness." *The Globe and Mail*, October 20, 2009, p. L6.

Reports

- 1) Canadian Breast Cancer Research Alliance. (2009). *National Breast Cancer Research Framework: A Roadmap for Research*. Toronto: CBCRA.
- 2) Canadian Breast Cancer Research Collaborative. (2016). *Monitoring of the National Breast Cancer Research Framework: A Report by the Canadian Breast Cancer Research Collaborative*. Toronto: CBCRC.
- 3) Canadian Cancer Society Research Institute. (2015). *Research Impact Report 2015*. Toronto: Canadian Cancer Society Research Institute.
https://issuu.com/canadiancancersociety/docs/ccsri_rir2015_en_jul2016_hires-fori?e=1256214/37135090
- 4) Canadian Institutes of Health Research. (2016) *Institute of Cancer Research Strategic Plan, 2015–2020: Capturing innovation to prevent cancer and improve cancer control for Canadians*. Ottawa: CIHR. <http://www.cihr-irsc.gc.ca/e/49894.html>
- 5) Crooks, D. (2012). Neglected issues. *Report Card on Cancer in Canada, 2011-12*, 14: 48.
- 6) Hryniuk, W. & Gillespie, D. (2008). Cancer research funding, Part Two. Where do our research dollars go...still? *Report Card on Cancer in Canada, 2007*, 10: 11–5.
- 7) Prostate Cancer Canada. (2012). *Environmental Scan of Prostate Cancer Research in Canada, 2005–2011*. Toronto: Prostate Cancer Canada.

Online Articles

- 1) Silversides, A. & Sullivan, T. (2012). Cancer research: should investments reflect disease burden? <http://healthydebate.ca/2012/10/topic/wa-it-times-access-to-care/cancer>

Presentations

- 1) Gotay, C. (2015). Trends in cancer research funding in Canada. <http://cc-arcc.ca/wp-content/uploads/2015/01/Current-gotay.pdf>

Theses

- 1) Cowling, A.E. (2014). *Yoga, Women, and Cancer: Experiences in a Specialized Yoga Program*. Master of Arts, York University, Toronto.

CCRA Strategic Plan

- 1) Joly, Y., Livingstone, A. & Dove, E.S. (2012). Moving beyond commercialization: Strategies to maximize the economic and social impact of genomics research. Policy Brief No. 5. Genome Canada.
- 2) Matzke, E.A.M. et al. (2012). Certification for Biobanks: The program developed by the Canadian Tumour Repository Network (CTRNet). *Biopreservation and Biobanking*, 10(5):426–32.

Prevention Research Framework

- 1) Ashbury, F.D. et al. (2014). A vision for chronic disease prevention and intervention research: Report from a workshop. *Canadian Journal of Public Health*, 105(2): e150-3.

Clinical Trials Report

- 1) Arts, K.E., Kato, D. & Dancey, J. (2015). Establishment of a baseline to measure academic clinical trial activity in Canada. 2015 ASCO Annual Meeting, *Journal of Clinical Oncology*, 33(suppl), Abstract e17547.
- 2) Bell, J.A.H. & Balneaves, L.G. (2015) Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients' relational autonomy. *Supportive Care in Cancer*, 23(4):1169–96.
- 3) Bell, J.A.H. et al. (2016). Report on a Delphi process and workshop to improve accrual to cancer clinical trials. *Current Oncology*, 23(2):125–30.
- 4) Dent, S.F. & Yurichuk, S. (2011). Should clinical trials be considered part of "standard of care"? *Report Card on Cancer in Canada, 2010-2011*, 13:23–9.
- 5) Grant, J. et al. (2016). Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors. 2016 ASCO Quality Care Symposium, *Journal of Clinical Oncology*, 34(suppl 7S), Abstract 219.
- 6) Hay, A.E. et al. (2016). Accrual of adolescents and young adults with cancer to clinical trials. *Current Oncology*, 23(2):e81–5.
- 7) Hébert, P.C. & Fergusson, D.A. (2010). Are we keeping research participants safe enough? *CMAJ*, 182(10):E428.
- 8) Lun, G. et al. (2013). Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medicine: A pilot project at a Canadian cancer center. *Clinical Genitourinary Cancer*, 11(3):342–5.
- 9) Meyer, R.M. et al. (2011). Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group perspective. *Canadian Urological Association Journal*, 5(6):379–81.
- 10) O'Leary, E. et al. (2013). Data collection in cancer clinical trials: Too much of a good thing? *Clinical Trials*, 0:1–9.
- 11) Price, A. et al. (2016). Mind the gap in clinical trials: A participatory action analysis with citizen collaborators. *Journal of Evaluation in Clinical Practice*. DOI: 10.1111/jep.12678.
- 12) Syme, R. et al. (2015) Integrating personalized medicine in the Canadian environment: Efforts facilitating oncology clinical research. *Public Health Genomics*, 18:372–80.
- 13) Thorne, S. et al. (2013). Of Guinea pigs and gratitude: the difficult discourse of clinical trials from the cancer patient perspective. *European Journal of Cancer Care*, 22(5):663–72.

CCRA itself

- 1) Knuttila, E. (2007). *Maximizing Patient Voices: Final Report*. Report produced for the Canadian Cancer Action Network.
- 2) Sullivan, R. et al. (2013). New policies to address the global burden of childhood cancers. *The Lancet Oncology*, 14(3):e125–35.
- 3) Wranik, W.D. et al. (2016). The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation? *The International Journal of Health Planning and Management*. DOI: 10.1002/hpm.2372